Biliary Tract Cancers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Cancer Type, By End-User, By Region & Competition, 2021-2031F

The Global Biliary Tract Cancers Market is projected to expand from USD 675.69 Million in 2025 to USD 892.63 Million by 2031, achieving a compound annual growth rate (CAGR) of 4.75%. This sector comprises diagnostic instruments and therapeutic agents tailored for malignancies originating in the bile ducts and gallbladder, such as cholangiocarcinoma and gallbladder carcinoma. Key factors driving this market trajectory include the rising prevalence of chronic liver diseases and global demographic shifts toward an aging population, alongside increased funding for molecular profiling to discover new treatment pathways. The American Cancer Society estimates that approximately 12,610 new cases of gallbladder and adjacent large bile duct cancers will be diagnosed in the United States in 2025.

However, the market faces significant obstacles due to the high frequency of diagnoses occurring at advanced disease stages. Symptoms typically appear only after the cancer has progressed substantially, making curative surgery unviable for most patients and limiting the effectiveness of many current treatments. This issue complicates clinical development and restricts the commercial viability of early intervention therapies, thereby hindering the overall expansion of the market.

Market Driver

The introduction of novel targeted therapies and immunotherapies is aggressively driving growth in the Global Biliary Tract Cancers Market by overcoming the historical limitations of standard chemotherapy. Pharmaceutical companies are utilizing genomic data to develop agents that specifically address molecular alterations like HER2 amplification and FGFR2 fusions. A major breakthrough was highlighted by Jazz Pharmaceuticals in a November 2024 press release titled 'FDA Approves Zanidatamab for Biliary Tract Cancer,' where the bispecific antibody zanidatamab achieved a confirmed objective response rate of 52% in patients with HER2-positive biliary tract cancer. These advancements improve clinical outcomes, decreasing reliance on palliative care and encouraging further investment in precision oncology.

Simultaneously, the rising global incidence of biliary tract malignancies serves as a primary driver, generating sustained demand for advanced diagnostic and therapeutic solutions. This growing disease burden results from factors such as aging populations and the increasing prevalence of chronic liver conditions. According to AstraZeneca's April 2024 press release, 'Imfinzi Plus Chemotherapy Doubled Overall Survival Rate,' roughly 210,000 individuals worldwide are diagnosed with biliary tract cancer annually, creating a significant need for effective clinical management. This trend is expected to continue, with the Multidisciplinary Digital Publishing Institute reporting in 2024 that incidence rates for intrahepatic cholangiocarcinoma are projected to reach 2.13 per 100,000 by 2029, emphasizing the urgent need for scalable therapies.

Market Challenge

A primary barrier to the Global Biliary Tract Cancers Market is the high rate of diagnosis at advanced disease stages. Since symptoms are often vague or undetected until the malignancy has significantly progressed, the vast majority of patients are ineligible for curative surgery, which restricts the use of adjuvant therapies. This limits the commercial landscape, forcing pharmaceutical developers to prioritize palliative care regimens that usually offer shorter treatment durations and lower success rates compared to early-stage interventions. Consequently, the lack of effective early detection methods diminishes the addressable market for high-value curative drugs, directly slowing sector growth.

The severe impact of these diagnostic delays is demonstrated by the poor prognosis for metastatic disease, which drastically reduces the patient pool eligible for long-term therapy. In 2024, the American Society of Clinical Oncology reported that the five-year relative survival rate for intrahepatic cholangiocarcinoma diagnosed at a distant stage is only 3 percent. This statistic highlights the difficulty in maintaining a robust market for therapies, as the advanced-stage patient population faces extremely high mortality rates, thereby limiting the window for therapeutic efficacy and revenue generation.

Market Trends

Pharmaceutical companies are increasingly seeking Orphan Drug Designations to expedite the development of new therapeutics for biliary tract cancers, bypassing regulatory hurdles associated with small patient populations. This strategy allows developers to obtain market exclusivity and financial incentives, which are essential for mitigating the risks of targeting rare malignancies with poor prognoses. An example of this trend is the development of liposomal formulations to enhance drug delivery in refractory cases; according to a BioSpace press release from July 2025 titled 'FF-10832 Granted FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer,' the FDA's designation for the investigational agent FF-10832 was based on the urgent need to address high recurrence rates of 50% to 70% in patients with unresectable or metastatic disease.

At the same time, clinical practice is shifting toward using liquid biopsies for non-invasive genomic characterization, enabling the precise detection of actionable mutations like FGFR2 fusions without the risks of invasive tissue sampling. This integration of routine molecular profiling allows oncologists to monitor tumor evolution and treatment resistance in real time, optimizing targeted therapy selection throughout care. The commercial appeal of these tools is evident as providers adopt blood-based assays; Guardant Health's April 2025 press release, 'Guardant Health Reports First Quarter 2025 Financial Results,' projected that oncology test volumes would grow by more than 25% in 2025, reflecting surging demand for comprehensive genomic profiling in advanced solid tumor management.

Key Market Players

• Bristol-Myers Squibb
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Bayer AG
• AstraZeneca plc

Report Scope

In this report, the Global Biliary Tract Cancers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biliary Tract Cancers Market, By Cancer Type

• Intrahepatic Cholangiocarcinoma (ICC)
• Extrahepatic Cholangiocarcinoma
• Gallbladder Cancer

Biliary Tract Cancers Market, By End-User

• Hospitals
• Specialty Cancer Centres
• Ambulatory Surgical Centres
• Others

Biliary Tract Cancers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biliary Tract Cancers Market.

Available Customizations:

Global Biliary Tract Cancers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).